Literature DB >> 14982804

In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae.

Lucio Vera-Cabrera1, Elsa Y Ochoa-Felix, Gloria Gonzalez, Rolando Tijerina, Sung H Choi, Oliverio Welsh.   

Abstract

In this work, we studied the in vitro sensitivity of 24 strains of Actinomadura madurae to a new oxazolidinone (DA-7867), gatifloxacin, moxifloxacin, and garenoxacin by using a broth microdilution method. We observed that the A. madurae strains had a high level of sensitivity to all the antimicrobials tested. The most active drug was DA-7867, with a MIC at which 90% of the strains are inhibited (MIC(90)) of 0.125 micro g/ml and a MIC(50) of 0.06 micro g/ml.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14982804      PMCID： PMC353109          DOI： 10.1128/AAC.48.3.1037-1039.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates.

Authors:  Lourdes Valera; Elizabeth Gradelski; Elizabeth Huczko; Thomas Washo; Hesna Yigit; Joan Fung-Tomc
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

2.  The in vitro activity of BMS-284756, a new des-fluorinated quinolone.

Authors:  T M A Weller; J M Andrews; G Jevons; R Wise
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

3.  Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.

Authors:  J A Hoogkamp-Korstanje; J Roelofs-Willemse
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

Review 4.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  In vitro activities of linezolid against multiple Nocardia species.

Authors:  B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.

Authors:  L Vera-Cabrera; A Gómez-Flores; W G Escalante-Fuentes; O Welsh
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  [Mycetoma: 130 cases].

Authors:  M-T Dieng; M-H Sy; B-M Diop; S-O Niang; B Ndiaye
Journal:  Ann Dermatol Venereol       Date:  2003-01       Impact factor: 0.777

8.  Clinical experience with linezolid for the treatment of nocardia infection.

Authors:  Edina H Moylett; Susan E Pacheco; Barbara A Brown-Elliott; Tracy R Perry; E Stephen Buescher; Mary C Birmingham; Jerome J Schentag; Joseph F Gimbel; Aaron Apodaca; Margot A Schwartz; Robert M Rakita; Richard J Wallace
Journal:  Clin Infect Dis       Date:  2003-01-13       Impact factor: 9.079

9.  Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma.

Authors:  O Welsh; E Sauceda; J Gonzalez; J Ocampo
Journal:  J Am Acad Dermatol       Date:  1987-09       Impact factor: 11.527

10.  [Epidemiology of mycetoma in Mexico: study of 2105 cases].

Authors:  R López Martínez; L J Méndez Tovar; P Lavalle; O Welsh; A Saúl; E Macotela Ruíz
Journal:  Gac Med Mex       Date:  1992 Jul-Aug       Impact factor: 0.302
View more
  7 in total

1.  In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Victor M Velazquez-Moreno; Sung Hak Choi; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.

Authors:  Lucio Vera-Cabrera; Barbara A Brown-Elliott; Richard J Wallace; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Carmen A Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

3.  Linezolid: A novel treatment option for the treatment of a non-responsive case of actinomycotic mycetoma.

Authors:  Suman Patra; Gridharan Senthilnathan; M Ramam; Sudheer Arava; Neetu Bhari
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

Review 4.  Prodrugs for the treatment of neglected diseases.

Authors:  Man Chin Chung; Elizabeth Igne Ferreira; Jean Leandro Santos; Jeanine Giarolla; Daniela Gonçales Rando; Adélia Emília Almeida; Priscila Longhin Bosquesi; Renato Farina Menegon; Lorena Blau
Journal:  Molecules       Date:  2007-03-19       Impact factor: 4.411

5.  Actinomycetoma by Actinomadura madurae: Clinical Characteristics and Treatment of 47 Cases.

Authors:  Alexandro Bonifaz; Andrés Tirado-Sánchez; Denisse Vazquez-Gonzalez; Javier Araiza; Rigoberto Hernández-Castro
Journal:  Indian Dermatol Online J       Date:  2021-02-22

6.  Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Alejandra Daw-Garza; Salvador Said-Fernández; Hector Gerardo Lozano-Garza; Noemi Waksman de Torres; Norma Cavazos Rocha; Jorge Ocampo-Candiani; Sung-Hak Choi; Oliverio Welsh
Journal:  PLoS Negl Trop Dis       Date:  2008-09-10

7.  Molecular identification of Actinomadura madurae isolated from a patient originally from Algeria; observations from a case report.

Authors:  Arezki Izri; Mohanad Aljundi; Typhaine Billard-Pomares; Youssouf Fofana; Anthony Marteau; Theo Ghelfenstein Ferreira; Sophie Brun; Frederic Caux; Mohammad Akhoundi
Journal:  BMC Infect Dis       Date:  2020-11-11       Impact factor: 3.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.